Advertisement
U.S. markets closed

Valneva SE (VALN)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
7.92-0.03 (-0.38%)
At close: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close7.95
Open7.92
Bid6.58 x 800
Ask8.74 x 900
Day's Range7.73 - 8.00
52 Week Range6.58 - 17.05
Volume4,629
Avg. Volume10,245
Market Cap549.6M
Beta (5Y Monthly)0.80
PE Ratio (TTM)N/A
EPS (TTM)-1.58
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est18.12
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for VALN

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Valneva SE
    Daily – Vickers Top Buyers & Sellers for 12/29/2023The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    3 months agoArgus Research
View more
  • GlobeNewswire

    Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate

    Saint-Herblain (France), March 26, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced the initiation of a Phase 1 clinical trial to investigate the the safety and immunogenicity of VLA1601, its second-generation adjuvanted inactivated vaccine candidate against the Zika virus (ZIKV). There are currently no preventive vaccines or effective treatments available against ZIKV. As such, this mosquito-borne disease remains a public health threat and is i

  • GlobeNewswire

    Valneva Announces Filing of 2023 Universal Registration Document and US Form 20-F

    Saint-Herblain (France), March 25, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, announced today the filing, on March 22, 2024, of its 2023 Universal Registration Document (URD) with the French Financial Markets Authority (AMF) under the filing number D.24-0157 and its Form 20-F with the U.S. Securities and Exchange Commission (SEC). Valneva’s 2023 Universal Registration Document – available in its entirety in French – includes the Company’s 2023 Annual Fina

  • Insider Monkey

    Valneva SE (NASDAQ:VALN) Q4 2023 Earnings Call Transcript

    Valneva SE (NASDAQ:VALN) Q4 2023 Earnings Call Transcript March 20, 2024 Valneva SE misses on earnings expectations. Reported EPS is $-0.46 EPS, expectations were $0.2. VALN isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Joshua Drumm: Thank you. Hello, and thank […]